Pharmafile Logo

Entresto

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Entresto in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Entresto.

20

Global Revenue Ranking

Recent articles on PMLiVE featuring Entresto

- PMLiVE
Drugmakers submit counteroffers to US Medicare pricing negotiations

New negotiated prices are set to be announced by 1 September 2024 and implemented in 2026

- PMLiVE
Novartis sues US government over Medicare drug price negotiation programme

The action comes after the first drugs subject to pricing negotiations were announced

- PMLiVE
US government announces first ten drugs subject to Medicare pricing negotiations

The IRA programme is facing court challenges from leading drugmakers and industry groups

- PMLiVE
Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz

The company has started a strategic review of Sandoz as sales drop 20% in ‘challenging’ US market

- PMLiVE
Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Swiss pharma company also provided key updates on a number of drug candidates in its pipeline

- PMLiVE
Novartis hit by ‘COVID-19-related lockdowns’ in Q4

Sales grew in the quarter but profits fell short of forecasts

- PMLiVE
Novartis weathers the COVID-19 storm in Q3, lifts outlook

Core operating income increased by 11%, profits from net income drop

- PMLiVE
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3

Drug hit primary endpoint but missed secondary endpoint of reduction in cardiovascular death

- PMLiVE
Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales

- PMLiVE
Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021

- PMLiVE
Merck, Bayer flesh out vericiguat heart failure data at ACC

Drug reduced rate of cardiovascular deaths and hospitalisations

- PMLiVE
20 for 2020 – Five pharma leaders to watch in 2020

Five individuals we think will have a key role to play in the sector in 2020 and beyond

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links